Beschreibung:
<jats:p> Diabetic neuropathic pain is a frequent complication of diabetic neuropathy. The specific manifestations of diabetic neuropathic pain include spontaneous pain and hyperalgesia, which seriously affect the quality of life of patients. Previous publications have shown that H<jats:sub>2</jats:sub>S has both pro-nociceptive and anti-nociceptive effects. This present investigation aimed to examine the anti-nociceptive effect of H<jats:sub>2</jats:sub>S on diabetic neuropathic pain. We established a diabetic neuropathic pain animal model with high-glucose, high-fat diet, and STZ, then treated rats with different concentrations of H<jats:sub>2</jats:sub>S and inhibitors of NOS, sGC, PKG, and opioid receptors. The mechanical allodynia and thermal hyperalgesia of rats were measured to assess the anti-nociceptive effects of H<jats:sub>2</jats:sub>S. The mRNA and protein expression of NOS and PKG1 were measured to explore their roles in the anti-nociceptive action of H<jats:sub>2</jats:sub>S. The results revealed that inhalation of H<jats:sub>2</jats:sub>S gas had anti-nociceptive effect in diabetic neuropathic pain model rats without affecting the blood glucose level and body mass. It increased the mRNA and protein level of nNOS, and the inhibitor of nNOS, 7-NI, abolished the anti-nociceptive effect of H<jats:sub>2</jats:sub>S. Furthermore, inhibitors of sGC and PKG could also abolish the anti-nociceptive effect of H<jats:sub>2</jats:sub>S. The expression of PKG1 was found to be increased by H<jats:sub>2</jats:sub>S, which was reversed by the inhibitors of nNOS, sGC, and PKG. Finally, CTOP, a μ-opioid receptor antagonist, abolished the anti-nociceptive effect of H<jats:sub>2</jats:sub>S, indicating that the μ-opioid receptor plays a role in the anti-nociceptive effect of H<jats:sub>2</jats:sub>S. In conclusion, the findings of this investigation suggest that hydrogen sulfide may attenuate the diabetic neuropathic pain through NO/cGMP/PKG pathway and μ-opioid receptor. </jats:p><jats:sec><jats:title>Impact statement</jats:title><jats:p> There are currently approximately 425 million diabetic patients worldwide, of which approximately 90% of patients with diabetes suffer from neuropathy. Diabetic neuropathic pain (DNP) is a common complication of diabetic neuropathy. Nearly half of the patients hospitalized with diabetes have pain symptoms or symptoms related to neurological injury, and the incidence increases with age and diabetic duration. Anti-DNP analgesics have either limited therapeutic effects or serious side effects or lack of clinical trials, which has limited their application. Physiopathological mechanisms and treatment of DNP remain a significant challenge. The present confirmed that inhalation of H<jats:sub>2</jats:sub>S may attenuate the diabetic neuropathic pain through NO/cGMP/PKG pathway and μ-opioid receptor. It provides us the animal study foundation for the application of H<jats:sub>2</jats:sub>S on the treatment of DNP and clarifies some target molecules in the pain modulation of DNP. </jats:p></jats:sec>